Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)

Germany · Delayed Price · Currency is EUR

6.00

+0.10 (1.69%)

At close: Jun 26, 2026

-25.47% (1Y)

Market Cap	252.22M -26.3%
Revenue (ttm)	177.41M +0.3%
Net Income	24.91M -7.3%
EPS	0.60 -7.3%
Shares Out	n/a
PE Ratio	10.13
Forward PE	n/a
Dividend	0.28 (4.70%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Open	6.00
Previous Close	5.90
Day's Range	6.00 - 6.00
52-Week Range	5.70 - 10.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About FRA:YB3

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation... [Read more]

Industry Commercial Physical and Biological Research

Founded 1957

Employees 1,522

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol YB3

Financial Performance

In fiscal year 2026, FRA:YB3's revenue was 32.52 billion, an increase of 0.35% compared to the previous year's 32.41 billion. Earnings were 4.57 billion, a decrease of -7.26%.

Financial numbers in JPY Financial Statements